Introduction
Executive Summary
Epilepsy: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
GWP42003-P: GW Research
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
CVL-865: Cereval therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
OPC-214870: Otsuka Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Epilepsy Key Companies
Epilepsy Key Products
Epilepsy- Unmet Needs
Epilepsy- Market Drivers and Barriers
Epilepsy- Future Perspectives and Conclusion
Epilepsy Analyst Views
Epilepsy Key Companies
Appendix

List of Tables
Table 1 Total Products for Epilepsy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Epilepsy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Key Companies
• Bial - Portela C S.A
• SK Life Science, Inc.
• GW Pharmaceuticals
• UCB Biopharma
• Eisai Inc.
• Takeda
• Xenon Pharmaceuticals
• Zogenix International
• PTC therapeutics
• Idorsia Pharmaceuticals
• Cerevel Therapeutics
• Jazz Pharmaceuticals
• Epygenix Therapeutics
• ES therapeutics
• Marinus Pharmaceuticals
• Janssen Research & Development
• Bio-Pharm Solutions
• Biogen
• Neurocrine Biosciences
• Pfizer
• PhytoTech Therapeutics
• Stoke Therapeutics
• Xenon Pharmaceuticals
• Aadi, LLC
• Otsuka Pharmaceutical
• Tilray
• NeuCyte
• SK Biopharmaceuticals
• Adamas Pharmaceuticals
• OB Pharmaceuticals
• Tevard Biosciences
• Corlieve Therapeutics
• Alexza Pharmaceuticals
• NobelPharma
• Praxis Precision medicines
• Arvelle Therapeutics
• Q-state Biosciences
• Pear Therapeutics
• Ovid Therapeutics
• Abraxis Bioscience
• AXONIS Therapeutics